CONNECTA Therapeutics begins Phase IIa trial of CTH120 for FXS

CONNECTA Therapeutics has started a Phase IIa trial to assess CTH120, a neuroplasticity modulator, in adult males with fragile X syndrome. Impaired neuroplasticity is central to neurodevelopmental disorders and contributes to clinical symptoms in conditions such as FXS. Credit: New Africa / Shutterstock.com. CONNECTA Therapeutics has commenced a Phase IIa trial to assess its lead programme, CTH120, a neuroplasticity modulator, in male adults living with fragile X syndrome (FXS), an inherited cause of intellectual disability. CTH120 is a new small molecule designed to target the tropomyosin receptor kinase B (TrkB), which regulates neuroplasticity, the brain’s capacity to form and adapt…

Source: Clinical Trials Arena